Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2

Journal Article · · Biochemistry
 [1];  [2];  [1];  [1];  [3];  [2];  [2];  [2];  [2];  [2];  [2];  [2];  [1]
  1. Harvard Medical School, Boston, MA (United States); Dana-Farber Cancer Inst., Boston, MA (United States)
  2. Novartis Inst. for Biomedical Research, Cambridge, MA (United States)
  3. Frederick National Lab. for Cancer Research, Frederick, MD (United States). Leidos Biomedical Research, Inc., Basic Science Program
+ Show Author Affiliations
The proto-oncogene PTPN11 encodes a cytoplasmic protein tyrosine phosphatase, SHP2, which is required for normal development and sustained activation of the Ras-MAPK signaling pathway. Germline mutations in SHP2 cause developmental disorders, and somatic mutations have been identified in childhood and adult cancers and drive leukemia in mice. Despite our knowledge of the PTPN11 variations associated with pathology, the structural and functional consequences of many disease-associated mutants remain poorly understood. Here, in this paper, we combine X-ray crystallography, small-angle X-ray scattering, and biochemistry to elucidate structural and mechanistic features of three cancer-associated SHP2 variants harboring single point mutations within the N-SH2:PTP interdomain autoinhibitory interface. Our findings directly compare the impact of each mutation on autoinhibition of the phosphatase and advance the development of structure-guided and mutation-specific SHP2 therapies.
Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
Novartis-Dana Farber Cancer Institute Drug Development Program; William Lawrence-Blanche Hughes Foundation; American Cancer Society
OSTI ID:
1249241
Journal Information:
Biochemistry, Journal Name: Biochemistry Journal Issue: 15 Vol. 55; ISSN 0006-2960
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (37)

Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase: Domain Opening in SHP2 Phosphatase journal March 2011
Fluorogenic Substrates Based on Fluorinated Umbelliferones for Continuous Assays of Phosphatases and β-Galactosidases journal August 1999
Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. journal May 1994
The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp journal June 1993
Crystal Structure of the Tyrosine Phosphatase SHP-2 journal February 1998
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling journal June 2003
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations journal February 2005
A Method for Helical RNA Global Structure Determination in Solution Using Small-Angle X-Ray Scattering and NMR Measurements journal October 2009
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia journal September 2006
Impact and progress in small and wide angle X-ray scattering (SAXS and WAXS) journal October 2013
Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations journal June 2014
Small-Angle X-ray Scattering and Calorimetric Studies of Thermal Conformational Change of Lysozyme Depending on pH journal February 1998
A Grb2-associated docking protein in EGF- and insulin-receptor signalling journal February 1996
Discovery and saturation analysis of cancer genes across 21 tumour types journal January 2014
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia journal April 2003
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome journal November 2001
Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation journal July 2004
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group journal September 2004
High resolution pair-distance distribution function P(r) of protein solutions journal February 2009
The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp. journal August 1993
Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains journal February 1995
Regulation of the Mitogen-activated Protein Kinase Signaling Pathway by SHP2 journal March 2002
Diverse Biochemical Properties of Shp2 Mutants: IMPLICATIONS FOR DISEASE PHENOTYPES journal June 2005
PRIMUS: a Windows PC-based system for small-angle scattering data analysis journal September 2003
New developments in the ATSAS program package for small-angle scattering data analysis journal March 2012
Determination of the regularization parameter in indirect-transform methods using perceptual criteria journal August 1992
CRYSOL – a Program to Evaluate X-ray Solution Scattering of Biological Macromolecules from Atomic Coordinates journal December 1995
XDS journal January 2010
Features and development of Coot journal March 2010
Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes journal June 2004
Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. journal October 1994
Binding of Shp2 Tyrosine Phosphatase to FRS2 Is Essential for Fibroblast Growth Factor-Induced PC12 Cell Differentiation journal July 1998
Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia journal December 2004
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia journal July 2004
Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia journal November 2005
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells journal July 2005
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11) journal January 2014

Cited By (4)

De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia journal May 2018
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2 journal October 2018
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition journal October 2018
Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099 journal August 2019

Similar Records

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
Journal Article · Tue Oct 30 00:00:00 EDT 2018 · Nature Communications · OSTI ID:1481293
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Journal Article · Wed Jun 29 00:00:00 EDT 2016 · Nature (London) · OSTI ID:1404986
Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation
Journal Article · Wed Feb 15 23:00:00 EST 2023 · Journal of Molecular Biology · OSTI ID:2423528

Related Subjects

60 APPLIED LIFE SCIENCES
Cancer
Conformation
Genetics
Peptides and proteins
X-ray scattering